Annals of Oncology 10:391-395, 1999
© 1999 European Society for Medical Oncology
other |
Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin
1Laboratory of Cancer Pharmacology, Department of Oncology, Istiluto di Ricerche Farmacologiche Mario Negri Milan, Italy
2Servizio Oncologico Ospedale San Giovanni, Bellinzona, Switzerland
3Islituto Europeo di Oncologia Milan, Italy
Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, 20157 Milan, Italy. E-mail: dincalci{at}irfmn.mnegri.it
Background: The combination of doxorubicin (Dx) with paclitaxel or docetaxel is clinically effective but there are concerns regarding the higher incidence of cardiotoxicity of the combination compared with Dx alone. The mechanism of the increased toxicity is still unclear.
Purpose: To assess whether there is a pharmacokinetic interaction between paclitaxel, docetaxel or their vehicles and Dx in mice.
Materials and methods: CDF1 male mice were treated with Dx either alone (10 mg/kg i.v.) or in combination with paclitaxel (25 mg/kg) or docetaxel (25 mg/kg) or their vehicles, i.e., cremophor-ethanol-glucose (cremophor) or polysorbate80-ethanol-glucose (polysorbate). Four mice were killed 4, 8 or 24 hours after Dx in each experimental group and Dx was assayed in serum and in heart, liver, kidney and spleen by HPLC.
Results: Four hours after treatment the concentrations of Dx in heart, liver and kidney were much higher in mice concomitantly treated with paclitaxel, docetaxel (dissolved in either cremophor or polysorbate) and cremophor. At subsequent times the differences were modest and only reached statistical significance in a few cases.
Dx metabolites were modified by concomitant treatment with taxanes or their vehicles. In particular, the levels of Dx aglycone in liver and kidney were significantly lower in mice treated with the combination than in mice given Dx alone.
Conclusions: paclitaxel, docetaxel and cremophor when given together with Dx modify its distribution and metabolism, increasing Dx levels in many tissues including the heart. This might have some bearing on the toxicity of regimens in which Dx is combined with taxanes.
docetaxel, doxorubicin, interaction, mice, paclitaxel, pharmacokinetics
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Cresta, G. Grasselli, M. Mansutti, A. Martoni, G. Lelli, G. Capri, F. Buzzi, G. Robustelli Della Cuna, A. Jirillo, E. Terzoli, et al. A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer Ann. Onc., March 1, 2004; 15(3): 433 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. To, M. Shin, M. Tabuchi, H. Sakaguchi, A. Takeuchi, N. Matsunaga, S. Higuchi, and S. Ohdo Influence of Dosing Schedule on Toxicity and Antitumor Effects of a Combination of Adriamycin and Docetaxel in Mice Clin. Cancer Res., January 15, 2004; 10(2): 762 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Agbulut, M.-L. Menot, Z. Li, F. Marotte, D. Paulin, A. A. Hagege, C. Chomienne, J.-L. Samuel, and P. Menasche Temporal patterns of bone marrow cell differentiation following transplantation in doxorubicin-induced cardiomyopathy Cardiovasc Res, May 1, 2003; 58(2): 451 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Giordano, D. J. Booser, J. L. Murray, N. K. Ibrahim, Z. U. Rahman, V. Valero, R. L. Theriault, M. F. Rosales, E. Rivera, D. Frye, et al. A Detailed Evaluation of Cardiac Toxicity: A Phase II Study of Doxorubicin and One- or Three-Hour-Infusion Paclitaxel in Patients with Metastatic Breast Cancer Clin. Cancer Res., November 1, 2002; 8(11): 3360 - 3368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Grasselli, L. Vigano, G. Capri, A. Locatelli, E. Tarenzi, C. Spreafico, A. Bertuzzi, A. Giani, C. Materazzo, S. Cresta, et al. Clinical and Pharmacologic Study of the Epirubicin and Paclitaxel Combination in Women With Metastatic Breast Cancer J. Clin. Oncol., April 15, 2001; 19(8): 2222 - 2231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Itoh, Y. Sasaki, H. Fujii, H. Minami, T. Ohtsu, H. Wakita, T. Igarashi, Y. Watanabe, Y. Onozawa, M. Kashimura, et al. Study of Dose Escalation and Sequence Switching of Administration of the Combination of Docetaxel and Doxorubicin in Advanced Breast Cancer Clin. Cancer Res., October 1, 2000; 6(10): 4082 - 4090. [Abstract] [Full Text]
|
|